dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Vahdat, Linda T. |
dc.contributor.author | Forero-Torres, Andres |
dc.contributor.author | Blackwell, Kimberly |
dc.contributor.author | Telli, Melinda L. |
dc.contributor.author | Melisko, Michelle |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Schmid, Peter |
dc.date.accessioned | 2022-02-22T11:26:34Z |
dc.date.available | 2022-02-22T11:26:34Z |
dc.date.issued | 2021-05-20 |
dc.identifier.citation | Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. NPJ Breast Cancer. 2021 May 20;7:57. |
dc.identifier.issn | 2374-4677 |
dc.identifier.uri | https://hdl.handle.net/11351/7063 |
dc.description | Càncer de mama; Càncer |
dc.description.sponsorship | Funding provided by Celldex Therapeutics, Inc. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | NPJ Breast Cancer;7 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Metàstasi |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Triple Negative Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoplasm Metastasis |
dc.subject.mesh | Treatment Outcome |
dc.title | Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41523-021-00244-6 |
dc.subject.decs | neoplasias de mama triple negativos |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | metástasis neoplásica |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1038/s41523-021-00244-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Vahdat LT] Weill Cornell Medicine, New York, NY, USA. [Schmid P] Center for Experimental Cancer Medicine, Barts Cancer Institute, London, UK. [Forero-Torres A] University of Alabama School of Medicine, Birmingham, AL, USA. [Blackwell K] Duke University Medical Center, Durham, NC, USA. [Telli ML] Stanford University School of Medicine, Stanford, CA, USA. [Melisko M] University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34016993 |
dc.identifier.wos | 000657821100002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |